Single-Agent Ibrutinib Active at 5 Years in CLL, SLL

Single-agent ibrutinib resulted in sustained efficacy and durable responses in treatment-naive or relapsed/refractory CLL or SLL, 5-year results show.

Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Immuno Oncology News Source Type: news